CY1119303T1 - Προφαρμακα πολυμερους πολλαπλων σκελων - Google Patents

Προφαρμακα πολυμερους πολλαπλων σκελων

Info

Publication number
CY1119303T1
CY1119303T1 CY20171100875T CY171100875T CY1119303T1 CY 1119303 T1 CY1119303 T1 CY 1119303T1 CY 20171100875 T CY20171100875 T CY 20171100875T CY 171100875 T CY171100875 T CY 171100875T CY 1119303 T1 CY1119303 T1 CY 1119303T1
Authority
CY
Cyprus
Prior art keywords
prodrugs
conjugates
soluble polymer
water soluble
water
Prior art date
Application number
CY20171100875T
Other languages
English (en)
Inventor
Xuan Zhao
Michael D Bentley
Zhongxu Ren
Tacey X Viegas
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of CY1119303T1 publication Critical patent/CY1119303T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyethers (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

Στο παρόν παρέχονται υδατοδιαλυτά προφάρμακα. Τα προφάρμακα της εφεύρεσης περιέχουν ένα υδατοδιαλυτό πολυμερές που έχει τρία ή περισσότερα σκέλη, τουλάχιστον τρία από τα οποία συνδέονται ομοσθενώς με έναν δραστικό παράγοντα, π.χ. ένα μικρό μόριο. Τα συζεύγματα της εφεύρεσης που παρέχονται σε βέλτιστη ισορροπία του πολυμερικού μεγέθους και τη δομή για την επίτευξη βελτιωμένης φόρτωσης φαρμάκου, καθώς τα συζεύγματα της εφεύρεσης διαθέτουν τρεις ή περισσότερους δραστικούς παράγοντες που συνδέονται με δυνατότητα αποδέσμευσης σε ένα υδατοδιαλυτό πολυμερές πολλαπλών σκελών. Τα προφάρμακα της εφεύρεσης είναι θεραπευτικώς αποτελεσματικά, και παρουσιάζουν βελτιωμένες ιδιότητες in vivo όταν συγκρίνονται με το μη τροποποιημένο αρχικό φάρμακο.
CY20171100875T 2003-09-17 2017-08-17 Προφαρμακα πολυμερους πολλαπλων σκελων CY1119303T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50367303P 2003-09-17 2003-09-17
US58430804P 2004-06-30 2004-06-30
PCT/US2004/030720 WO2005028539A2 (en) 2003-09-17 2004-09-17 Multi-arm polymer prodrugs

Publications (1)

Publication Number Publication Date
CY1119303T1 true CY1119303T1 (el) 2018-02-14

Family

ID=34381082

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100875T CY1119303T1 (el) 2003-09-17 2017-08-17 Προφαρμακα πολυμερους πολλαπλων σκελων

Country Status (18)

Country Link
US (4) US7744861B2 (el)
EP (2) EP1675622B1 (el)
JP (4) JP5632119B2 (el)
KR (2) KR20120073370A (el)
CN (2) CN1852740B (el)
AU (2) AU2004274489B2 (el)
BR (1) BRPI0414017B8 (el)
CA (1) CA2537336C (el)
CY (1) CY1119303T1 (el)
DK (1) DK1675622T3 (el)
ES (1) ES2629696T3 (el)
HR (1) HRP20171094T1 (el)
HU (1) HUE036290T2 (el)
LT (1) LT1675622T (el)
PL (1) PL1675622T3 (el)
PT (1) PT1675622T (el)
SI (1) SI1675622T1 (el)
WO (1) WO2005028539A2 (el)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
KR20120073370A (ko) * 2003-09-17 2012-07-04 넥타르 테라퓨틱스 다분지형 고분자 전구약물
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
US20070160622A1 (en) * 2005-12-07 2007-07-12 Medivas, Llc Method for assembling a polymer-biologic delivery composition
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
RU2404980C2 (ru) * 2005-05-11 2010-11-27 Ниппон Каяку Кабусики Кайся Полимерное производное антиметаболита цитидина
US9346029B2 (en) 2005-06-06 2016-05-24 The University Of British Columbia Polymer-based serum albumin substitute
US8728493B2 (en) 2005-06-17 2014-05-20 Nektar Therapeutics Polymer based compositions and conjugates of non-steroidal anti-inflammatory drugs
US8445007B2 (en) 2005-09-22 2013-05-21 Medivas, Llc Bis-(α-amino)-diol-diester-containing poly (ester amide) and poly (ester urethane) compositions and methods of use
EP1933881B1 (en) * 2005-09-22 2019-03-13 Medivas, LLC Solid polymer delivery compositions and methods for use thereof
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
US9603941B2 (en) * 2006-01-24 2017-03-28 Minghui Chai Method of preparing dendritic drugs
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
TWI426905B (zh) * 2006-02-09 2014-02-21 Enzon Pharmaceuticals Inc 用於乳癌、大腸直腸癌、胰臟癌、卵巢癌及肺癌之治療的７-乙基-１０羥喜樹鹼之多臂聚合性共軛物
SI1988910T1 (en) 2006-02-28 2018-02-28 Kodiak Sciences Inc. Polymeric conjugates containing acryloyloxyethylphosphorylcholine and their preparations
US20070292476A1 (en) * 2006-05-02 2007-12-20 Medivas, Llc Delivery of ophthalmologic agents to the exterior or interior of the eye
JP5196498B2 (ja) * 2006-05-09 2013-05-15 メディバス エルエルシー 生分解性水溶性ポリマー
JP5630998B2 (ja) 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
CA2669541C (en) * 2006-11-30 2014-11-18 Nektar Therapeutics Al, Corporation Method for preparing a polymer conjugate
JP2010518120A (ja) * 2007-02-09 2010-05-27 エンゾン ファーマスーティカルズ インコーポレイテッド ７−エチル−１０−ヒドロキシカンプトテシンのマルチアームポリマー複合体を用いた抵抗性または難治性の癌の治療方法
WO2008098165A2 (en) 2007-02-09 2008-08-14 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
JP5428017B2 (ja) * 2007-03-23 2014-02-26 国立大学法人 熊本大学 ワクチン剤
WO2008124632A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
WO2008144067A1 (en) * 2007-05-21 2008-11-27 Board Of Regents, University Of Texas System Methods and compositions for treatment of cancer using oncolytic rsv activity
US20090029937A1 (en) * 2007-07-24 2009-01-29 Cornell University Biodegradable cationic polymer gene transfer compositions and methods of use
CN101835482A (zh) * 2007-08-20 2010-09-15 安佐制药股份有限公司 含吡啶基二硫化物部分的聚合连接基
CA2713185A1 (en) * 2007-08-23 2009-02-26 Medivas, Llc Cationic alpha-amino acid-containing biodegradable polymer gene transfer compositions
WO2009043027A2 (en) * 2007-09-27 2009-04-02 Serina Therapeutics, Inc. Multi-armed forms of activated polyoxazoline and methods of synthesis thereof
AU2008314647B2 (en) 2007-10-12 2013-03-21 Massachusetts Institute Of Technology Vaccine nanotechnology
US8853247B2 (en) 2007-11-02 2014-10-07 Nektar Therapeutics Oligomer-nitroimidazole anti-infective conjugates
EP2216049A1 (en) * 2009-02-06 2010-08-11 Freie Universität Berlin Drug conjugates with polyglycerols
EP2268315B1 (en) * 2008-03-31 2019-07-31 Freie Universität Berlin Drug conjugates with polyglycerols
WO2009124386A1 (en) * 2008-04-07 2009-10-15 Interface Biologics Inc. Combination therapy for the treatment of bacterial infections
KR101671537B1 (ko) * 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
CA2733686A1 (en) * 2008-08-13 2010-02-18 Medivas, Llc Aabb-poly(depsipeptide) biodegradable polymers and methods of use
TW201010732A (en) * 2008-08-29 2010-03-16 Enzon Pharmaceuticals Inc Method of treating RAS associated cancer
EP2350118B1 (en) 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
EP2334338A2 (en) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of c-peptides
SI2349346T1 (sl) * 2008-09-23 2019-12-31 Nektar Therapeutics Postopek metronomskega doziranja s kamptotekinskim predzdravilom (npr. PEG-irinotekan)
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
KR20110075029A (ko) * 2008-10-21 2011-07-05 엔즌 파마슈티칼스, 인코포레이티드 7-에틸-10-하이드록시캄토테신의 다중-암 고분자 컨쥬게이트로 신경모세포종의 치료
KR20100083632A (ko) * 2009-01-14 2010-07-22 울산대학교 산학협력단 표적 단백질 분해효소 감응형 항암제 전구체
CA2760771A1 (en) * 2009-05-04 2010-11-11 Intezyne Technologies, Incorporated Polymer micelles containing sn-38 for the treatment of cancer
US20120171201A1 (en) * 2009-07-22 2012-07-05 Enzon Pharmaceuticals, Inc. Methods of treating her2 positive cancer with her2 receptor antagonist in combination with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
US8722732B2 (en) 2009-09-29 2014-05-13 Nektar Therapeutics Oligomer-calcimimetic conjugates and related compounds
RS58901B1 (sr) * 2009-11-18 2019-08-30 Nektar Therapeutics Oblici kisele soli konjugata polimer-lek
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
CN106432747B (zh) 2010-03-01 2019-11-05 不列颠哥伦比亚大学 衍生的超支化聚丙三醇
EP2571896A4 (en) 2010-05-17 2014-01-08 Cebix Inc PEGYLATED C-PEPTIDE
CN102339813A (zh) 2010-07-14 2012-02-01 中国科学院微电子研究所 半导体结构及其制造方法
EP2593021A4 (en) * 2010-07-16 2018-01-24 Kensey Nash Corporation Bioadhesive compounds and methods of synthesis and use
AU2011282983A1 (en) * 2010-07-28 2013-02-21 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
US8524215B2 (en) * 2010-08-02 2013-09-03 Janssen Biotech, Inc. Absorbable PEG-based hydrogels
WO2012083197A1 (en) * 2010-12-17 2012-06-21 Nektar Therapeutics Water-soluble polymer conjugates of topotecan
EP2654795B1 (en) * 2010-12-21 2018-03-07 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088522A1 (en) 2010-12-23 2012-06-28 Nektar Therapeutics Polymer-des-ethyl sunitinib conjugates
EP2654799B1 (en) 2010-12-23 2017-11-08 Nektar Therapeutics Polymer-sunitinib conjugates
WO2012162175A1 (en) 2011-05-20 2012-11-29 Howard University Emetine derivatives, prodrugs containing same, and methods of treating conditions using same
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
WO2012177825A1 (en) 2011-06-21 2012-12-27 Bvw Holding Ag Medical device comprising boswellic acid
EP3159368B1 (en) 2011-06-23 2024-07-24 DSM IP Assets B.V. New biodegradable polyesteramide copolymers for drug delivery
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
EP2741778A1 (en) 2011-08-12 2014-06-18 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
CA2843875C (en) 2011-08-12 2020-01-07 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
CN102935066B (zh) * 2011-08-16 2014-09-17 齐鲁制药有限公司 一种伊立替康脂质体制剂及其制备方法
JP6138140B2 (ja) * 2011-10-25 2017-05-31 ネクター セラピューティクス 癌患者の治療
US8383093B1 (en) * 2011-11-01 2013-02-26 Serina Therapeutics, Inc. Subcutaneous delivery of poly(oxazoline) conjugates
CN103083680B (zh) 2011-11-07 2014-12-24 北京键凯科技有限公司 聚乙二醇-氨基酸寡肽-依诺替康药物结合物及其药物组合物
RU2493848C1 (ru) * 2012-06-14 2013-09-27 Геннадий Петрович Власов Биодеградируемый полимерный носитель для доставки противоопухолевого лекарственного средства (варианты)
JP6300460B2 (ja) * 2012-07-20 2018-03-28 キヤノン株式会社 化合物、および前記化合物を有する光音響イメージング用造影剤
WO2014085571A1 (en) * 2012-11-28 2014-06-05 Nektar Therapeutics Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase i inhibitor
EP3004888A1 (en) 2013-05-31 2016-04-13 Nektar Therapeutics Method for predicting and evaluating responsiveness to cancer treatment with dna-damaging chemotherapeutic agents
CA3172586A1 (en) 2013-07-31 2015-02-05 Avalyn Pharma Inc. Aerosol imatininb compounds and uses thereof
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
EP3760639A1 (en) 2013-09-08 2021-01-06 Kodiak Sciences Inc. Zwitterionic polymer conjugates
JP5721806B2 (ja) * 2013-10-04 2015-05-20 Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社 副作用のない抗癌剤
KR102320753B1 (ko) * 2013-10-04 2021-11-02 프로린크스 엘엘시 Sn-38 서방성 컨쥬게이트
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2015206667B2 (en) * 2014-01-14 2020-05-14 Nektar Therapeutics Combination-based treatment method
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
JP6849590B2 (ja) 2014-10-17 2021-03-24 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
RU2697551C2 (ru) * 2014-12-04 2019-08-15 Дельта-Флай Фарма, Инк. Новые производные peg
CN107106509B (zh) 2014-12-18 2021-11-30 帝斯曼知识产权资产管理有限公司 用于递送酸敏感药物的药物递送系统
IL260323B1 (en) 2015-12-30 2024-09-01 Kodiak Sciences Inc Antibodies and their conjugates
CN107375288B (zh) * 2016-05-16 2019-08-23 博瑞生物医药（苏州）股份有限公司 多臂的聚合靶向抗癌偶联物
ES2910987T3 (es) * 2016-08-09 2022-05-17 Univ Liverpool Composiciones oftálmicas
JP7250679B2 (ja) 2017-01-10 2023-04-03 ネクター セラピューティクス Ｔｌｒ作動薬化合物のマルチアームポリマーコンジュゲート及び関連の免疫療法治療の方法
JP2020105072A (ja) * 2017-03-24 2020-07-09 協和キリン株式会社 ポリエチレングリコール誘導体
ES2859473T3 (es) * 2017-04-21 2021-10-04 Bright Gene Bio Medical Tech Co Ltd Conjugado anticanceroso dirigido de múltiples brazos
CN108727584B (zh) * 2017-04-21 2021-01-05 博瑞生物医药（苏州）股份有限公司 抗癌偶联物
WO2019014267A1 (en) 2017-07-11 2019-01-17 Synthorx, Inc. INCORPORATION OF NON-NATURAL NUCLEOTIDES AND ASSOCIATED METHODS
AU2018309172B2 (en) 2017-08-03 2022-12-15 Synthorx, Inc. Cytokine conjugates for the treatment of autoimmune diseases
WO2019096096A1 (zh) * 2017-11-14 2019-05-23 博瑞生物医药（苏州）股份有限公司 多臂靶向偶联物
CN109776788B (zh) * 2017-11-14 2021-07-30 博瑞生物医药（苏州）股份有限公司 叶酸受体靶向多臂偶联物
CN109771658B (zh) * 2017-11-14 2021-12-10 博瑞生物医药（苏州）股份有限公司 靶向多臂偶联物
CN109776787B (zh) * 2017-11-14 2021-08-03 博瑞生物医药（苏州）股份有限公司 多臂靶向偶联物
WO2019136453A1 (en) * 2018-01-08 2019-07-11 The Regents Of The University Of Colorado, A Body Corporate 3d in vitro models of lung tissue
AU2019208024A1 (en) 2018-01-12 2020-08-13 Prolynx Llc Protocol for minimizing toxicity of combination dosages and imaging agent for verification
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
EP3852793A4 (en) 2018-09-17 2022-07-13 The Children's Hospital Of Philadelphia MACROMOLECULAR POLYMER-BASED PRODRUGS
WO2020081684A1 (en) * 2018-10-16 2020-04-23 Rensselaer Polytechnic Institute Synthesis and processing of poly(pro-drug) materials for extended drug release and uses thereof
EP3923974A4 (en) 2019-02-06 2023-02-08 Synthorx, Inc. IL-2 CONJUGATES AND METHODS OF USE THEREOF
CN111603567A (zh) 2019-02-22 2020-09-01 博瑞生物医药（苏州）股份有限公司 Cd44靶向多臂偶联物
CN114222777B (zh) * 2019-08-28 2024-05-14 波士顿科学国际有限公司 多臂聚恶唑啉和与其相关的组合物、系统和方法
WO2021041225A1 (en) * 2019-08-28 2021-03-04 Boston Scientific Scimed, Inc. Multi-armed polymers comprising free-radical-polymerizable monomers
TW202124385A (zh) 2019-09-10 2021-07-01 美商欣爍克斯公司 治療自體免疫疾病之il-2接合物及使用方法
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
KR20220097445A (ko) 2019-11-04 2022-07-07 신톡스, 인크. 인터류킨 10 접합체 및 이의 용도
ES2965179T3 (es) 2020-05-14 2024-04-11 Delta Fly Pharma Inc Derivado polimérico soluble en agua de venetoclax

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
WO1993024476A1 (en) * 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5614549A (en) 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
TW438775B (en) * 1995-04-07 2001-06-07 Pharmacia & Upjohn Co Llc Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
HUP9901069A2 (hu) 1995-06-07 1999-07-28 Affymax Technologies, N.V. Az eritropoietin receptorhoz kötődő vegyületek és peptidek
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
SI0932399T1 (sl) 1996-03-12 2006-10-31 Pg Txl Co Lp Vodotopna paklitakselna predzdravila
FR2746308B1 (fr) 1996-03-22 1998-04-30 Oreal Compositions de teinture des fibres keratiniques contenant des imidazolo-azoles ; leur utilisation en teinture comme coupleurs ; procede de teinture
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6111107A (en) 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
US6624142B2 (en) * 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
JP4078032B2 (ja) 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル，コーポレイション 近位の反応性基を持つポリ（エチレングリコール）誘導体
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
DE29812626U1 (de) 1998-07-15 1998-11-12 SCM Microsystems GmbH, 85276 Pfaffenhofen Kartenleser für Chipkarten
EP1176985A2 (en) 1999-04-28 2002-02-06 Vectramed, Inc. Enzymatically activated polymeric drug conjugates
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6541508B2 (en) 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
AU781839B2 (en) * 1999-12-22 2005-06-16 Nektar Therapeutics Sterically hindered derivatives of water soluble polymers
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
US6602498B2 (en) * 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
AU2001257577A1 (en) * 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
US6777387B2 (en) * 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
US6756037B2 (en) * 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
US6629995B1 (en) * 2000-03-31 2003-10-07 Super Gen, Inc. Camptothecin conjugates
CA2416511C (en) 2000-07-21 2012-05-08 Martin D. Hurlimann Nuclear magnetic resonance methods for extracting information about a fluid in a rock
AU2002217981A1 (en) 2000-11-30 2002-06-11 Cornerstone Pharmaceuticals, Inc. Water-soluble polymer conjugates of triazine derivatives
US8552054B2 (en) * 2001-03-23 2013-10-08 Luitpold Pharmaceuticals, Inc. Fatty amine drug conjugates
US20030108556A1 (en) * 2001-06-08 2003-06-12 Mekalanos John J. Therapeutic uses of polyvalent compositions in infectious diseases
WO2003033525A1 (en) 2001-10-12 2003-04-24 Debio Recherche Pharmacuetique S.A. Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
JP2005508365A (ja) * 2001-10-29 2005-03-31 ネクター セラピューティックス エイエル，コーポレイション プロテインキナーゼｃインヒビターのポリマー結合体
MXPA04004025A (es) * 2001-10-30 2004-07-08 Nektar Therapeutics Al Corp Conjugados polimericos de acido retinoico solubles en agua.
US6608076B1 (en) 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
AU2003243418B2 (en) * 2002-06-06 2009-02-19 University Of Washington Covalent conjugates between artemisinin-related endoperoxides and iron-carrying proteins and methods of use
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
CN102516417B (zh) * 2002-09-06 2014-12-10 天蓝制药公司 用于传递治疗剂的以环糊精为基础的聚合物
KR20120073370A (ko) 2003-09-17 2012-07-04 넥타르 테라퓨틱스 다분지형 고분자 전구약물

Also Published As

Publication number Publication date
CA2537336C (en) 2013-02-26
AU2004274489A1 (en) 2005-03-31
JP5632119B2 (ja) 2014-11-26
LT1675622T (lt) 2017-09-11
BRPI0414017B8 (pt) 2021-05-25
KR20060090705A (ko) 2006-08-14
JP2011213727A (ja) 2011-10-27
JP2007505928A (ja) 2007-03-15
CN102172405B (zh) 2014-11-12
EP1675622A2 (en) 2006-07-05
CN1852740A (zh) 2006-10-25
DK1675622T3 (en) 2017-09-18
US20050112088A1 (en) 2005-05-26
EP2626083A1 (en) 2013-08-14
JP2017119706A (ja) 2017-07-06
CN1852740B (zh) 2011-05-11
BRPI0414017A (pt) 2006-09-05
WO2005028539A3 (en) 2005-11-24
KR101200729B1 (ko) 2012-11-13
PL1675622T3 (pl) 2017-11-30
US7744861B2 (en) 2010-06-29
HUE036290T2 (hu) 2018-06-28
AU2011202402B2 (en) 2013-12-12
US8263062B2 (en) 2012-09-11
KR20120073370A (ko) 2012-07-04
US20100190933A1 (en) 2010-07-29
CN102172405A (zh) 2011-09-07
AU2011202402A1 (en) 2011-06-09
WO2005028539A2 (en) 2005-03-31
PT1675622T (pt) 2017-09-19
AU2004274489B2 (en) 2011-06-09
EP1675622B1 (en) 2017-06-14
BRPI0414017B1 (pt) 2019-04-09
CA2537336A1 (en) 2005-03-31
ES2629696T3 (es) 2017-08-14
HRP20171094T1 (hr) 2017-10-06
US20100152414A1 (en) 2010-06-17
US20080194612A1 (en) 2008-08-14
US8318145B2 (en) 2012-11-27
JP6166014B2 (ja) 2017-07-19
SI1675622T1 (sl) 2017-09-29
JP2014196321A (ja) 2014-10-16
BRPI0414017A8 (pt) 2018-04-24

Similar Documents

Publication Publication Date Title
CY1119303T1 (el) Προφαρμακα πολυμερους πολλαπλων σκελων
CY1123384T1 (el) Κατευθυνομενη απο θεση τροποποιηση toy fviii
CY1110609T1 (el) Μεθοδος για την παρασκευη μιας διασφαλισμενης εναντια σε καταχρηση μορφης χορηγησης
CY1114132T1 (el) Γαστροανθεκτικες φαρμακοτεχνικες μορφες που περιεχουν ριφαξιμινη
CY1115715T1 (el) Διαλυτοποιηση και στοχευομενη χορηγηση δραστικων ουσιων με αυτο-οργανουμενα αμφιφιλα πολυμερη
CY1114992T1 (el) Μονοδιεσπαρμενες πεγκυλιωμενες συνθεσεις ναλοξολης
CY1123724T1 (el) Φαρμακευτικη συνθεση για τροποποιημενη αποδεσμευση
CY1112278T1 (el) Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαυμυciν και η θεραπευτικη χρηση τους
CY1116616T1 (el) Θεραπευτικη αγωγη ογκων του μαστου με παραγωγο ραπαμυκινης σε συνδυασμο με εξεμεστανη
CY1115354T1 (el) Ενωσεις πεγκυλιωμενης ινσουλινης lispro
WO2017112826A3 (en) Polymer conjugates having reduced antigenicity and methods of using the same
CY1117161T1 (el) Βελτιωμενοι κυτταροτοξικοι παραγοντες οι οποιοι περιεχουν νεα μεϋτανσινοειδη
CY1108183T1 (el) Θειαζολυλο-διυδρο-ινδαζολια
CY1117897T1 (el) Αναστολεις κινασης τυροσινης bruton
CY1116023T1 (el) Μορφες φαρμακευτικης δοσολογιας παρατεταμενης απελευθερωσης με περιγραμματα διαλυτοποιησης ελαχιστοποιημενης εξαρτησης απο το ph
HK1146075A1 (en) Polyglutamate-amino acid conjugates and methods
MXPA03011094A (es) Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello.
CY1109644T1 (el) 2,4-διαμινο-πυριμιδινες ως αναστολεις audora
DE60223499D1 (de) Terminal verzweigte, polymere linker und diese enthaltende polymere konjugate
TW200635576A (en) Releasable polymeric conjugates based on aliphatic biodegradable linkers
CY1107644T1 (el) Διασφαλισμενη εναντια σε καταχρηση μορφη χορηγησης
CY1107738T1 (el) Διασφαλισμενη εναντια σε καταχρηση μορφη χορηγησης
MX2011009808A (es) Agentes de elaboracion de imagen optica.
WO2010039496A3 (en) Nanocarriers for drug delivery
CY1109744T1 (el) Συζυγη και μεθοδοι για την παραγωγη τους, και η χρηση τους για την μεταφορα μοριων δια μεσου βιολογικων μεμβρανων